Discovery of novel synthetic IL-1 adjuvants

新型合成 IL-1 佐剂的发现

• 批准号: 10610274
• 负责人: JAY EVANS
• 金额: $ 261.3万
• 依托单位: UNIVERSITY OF MONTANA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2022-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10610274
• 关键词: Adjuvant; Contractor; Disease; Formulation; Infection; Interleukin-1; Interleukin-1 Receptors; Libraries; Peptide aptamers; Pharmaceutical Chemistry; Recombinant Vaccines; Side; Testing; Vaccine Adjuvant; Vaccines; immunogenicity; influenza virus vaccine; novel; small molecule; synthetic peptide; vaccine evaluation

To identify the optimal adjuvant for recombinant vaccines and inactivated flu vaccines, and to identify correlates of protection against infection or disease, experimental vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.

为了确定重组疫苗和灭活流感疫苗的最佳佐剂，并确定预防感染或疾病的相关性，将用一组不同的疫苗佐剂配制实验疫苗，并并排测试免疫原性和功效。